At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 800 enrolled
Drug / intervention
Thalidomide +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
IFM 99-02 Thalidomide in Myeloma
In Brief
A Phase 3 clinical trial evaluating Thalidomide and Biphosphonates for Multiple Myeloma. Completed, enrolled 800 participants across 5 sites.
Detailed Summary
Principal objective is to evaluate the impact of Thalidomide to prolong the duration of response after autologous transplantation for myeloma
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMultiple Myeloma
CountriesFrance
Collaborators--
Timeline
Phase 3CompletedFinished
2000200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartApr 2000
First PostedSep 2005
Primary CompletionSep 2009
Study CompletionDec 2009
TodayJul 2026
First PostedSep 22, 2005
Enrollment StartApr 1, 2000
Primary CompletionSep 1, 2009
Study CompletionDec 1, 2009
TodayJul 2, 2026
Enrollment to primary: 9.4 yearsPosted 20.8 years ago
Interventions
Thalidomidedrug
Per os thalidomide
Biphosphonatesdrug
Biphosphonates